SI3658192T1 - Agonist glukokortikoidnega receptorja in njegovi imunokonjugati - Google Patents

Agonist glukokortikoidnega receptorja in njegovi imunokonjugati

Info

Publication number
SI3658192T1
SI3658192T1 SI201830305T SI201830305T SI3658192T1 SI 3658192 T1 SI3658192 T1 SI 3658192T1 SI 201830305 T SI201830305 T SI 201830305T SI 201830305 T SI201830305 T SI 201830305T SI 3658192 T1 SI3658192 T1 SI 3658192T1
Authority
SI
Slovenia
Prior art keywords
immunoconjugates
receptor agonist
glucocorticoid receptor
glucocorticoid
agonist
Prior art date
Application number
SI201830305T
Other languages
English (en)
Inventor
Adrian D. Hobson
Michael J. Mcpherson
Wendy Waegell
Christian Goess
Axel HERNANDEZ Jr.
Lu Wang
Christopher C. Marvin
Ling C. Santora
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of SI3658192T1 publication Critical patent/SI3658192T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SI201830305T 2017-12-01 2018-11-29 Agonist glukokortikoidnega receptorja in njegovi imunokonjugati SI3658192T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762593776P 2017-12-01 2017-12-01
US201762595054P 2017-12-05 2017-12-05
EP18833113.6A EP3658192B1 (en) 2017-12-01 2018-11-29 Glucocorticoid receptor agonist and immunoconjugates thereof
PCT/IB2018/059482 WO2019106609A1 (en) 2017-12-01 2018-11-29 Glucocorticoid receptor agonist and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
SI3658192T1 true SI3658192T1 (sl) 2021-08-31

Family

ID=65010803

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830305T SI3658192T1 (sl) 2017-12-01 2018-11-29 Agonist glukokortikoidnega receptorja in njegovi imunokonjugati

Country Status (34)

Country Link
US (2) US10772970B2 (sl)
EP (2) EP3884962A1 (sl)
JP (2) JP6813712B2 (sl)
KR (1) KR20200095477A (sl)
CN (1) CN111417410B (sl)
AU (1) AU2018374634A1 (sl)
BR (1) BR112020010694A2 (sl)
CA (1) CA3082356A1 (sl)
CL (2) CL2020001452A1 (sl)
CO (1) CO2020006446A2 (sl)
CR (1) CR20200239A (sl)
CY (1) CY1124230T1 (sl)
DK (1) DK3658192T3 (sl)
DO (1) DOP2020000116A (sl)
EC (1) ECSP20029001A (sl)
ES (1) ES2877659T3 (sl)
HR (1) HRP20210917T1 (sl)
HU (1) HUE054428T2 (sl)
IL (1) IL274651B (sl)
LT (1) LT3658192T (sl)
MA (1) MA49796A (sl)
MX (1) MX2020005583A (sl)
PE (1) PE20201286A1 (sl)
PL (1) PL3658192T3 (sl)
PT (1) PT3658192T (sl)
RS (1) RS61994B1 (sl)
RU (1) RU2020117698A (sl)
SG (1) SG11202004867WA (sl)
SI (1) SI3658192T1 (sl)
TW (1) TWI803542B (sl)
UA (1) UA126595C2 (sl)
UY (1) UY37991A (sl)
WO (1) WO2019106609A1 (sl)
ZA (1) ZA202003325B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20201286A1 (es) * 2017-12-01 2020-11-24 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados de este
AU2021261386A1 (en) * 2020-04-22 2022-11-24 Immunext, Inc. Anti-human vista antibodies and use thereof
CA3207416A1 (en) * 2021-02-04 2022-08-11 Lingjian ZHU Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
TW202304462A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023025248A1 (zh) * 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途
TW202340252A (zh) * 2022-01-29 2023-10-16 大陸商上海盛迪醫藥有限公司 糖皮質激素的藥物偶聯物
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
GB933868A (en) 1958-12-08 1963-08-14 American Cyanamid Co Process for fluorinating steroids
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5010176A (en) 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
NZ265054A (en) 1993-04-02 1997-08-22 Byk Gulden Lomberg Chem Fab 16-hydroxy prednisolone cyclohexanecarboxaldehyde acetal derivatives
WO1994025478A1 (en) 1993-04-29 1994-11-10 Instytut Farmaceutyczny 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES
EP0749438B1 (de) 1994-03-09 2000-12-13 Byk Gulden Lomberg Chemische Fabrik GmbH Neue silylverbindungen und ihre verwendung
JP2749778B2 (ja) 1994-09-05 1998-05-13 日清食品株式会社 トリアムシノロン誘導体
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE10055820C1 (de) 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
EA006231B1 (ru) 2000-11-10 2005-10-27 Алтана Фарма Аг Способ получения 16,17-[(циклогексилметилен)бис(окси)]-11,21-дигидроксипрегна-1,4-диен-3,20-диона или его 21-изобутирата транскетализацией
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
CN1585778A (zh) 2001-11-12 2005-02-23 默克专利有限公司 修饰的抗－TNFα抗体
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004017904A2 (en) 2002-08-23 2004-03-04 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
EP1567113A4 (en) 2002-10-24 2006-11-08 G & R Pharmaceuticals Llc ANTIFUNGAL PREPARATIONS
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AR042461A1 (es) 2002-12-13 2005-06-22 Neurogen Corp Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas
AU2004207003A1 (en) 2003-01-30 2004-08-12 Medimmune, Llc Anti-integrin alphanubeta3 antibody formulations and uses thereof
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
WO2005044759A2 (en) 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
WO2005028495A1 (en) 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
EP1680073B1 (en) 2003-10-21 2013-01-02 IGF Oncology, LLC Compounds and method for treating cancer
CN100455582C (zh) 2003-11-13 2009-01-28 霍夫曼-拉罗奇有限公司 羟烷基取代的吡啶并-7-嘧啶-7-酮
EP1697370B1 (en) 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
EP1729724A4 (en) 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
JP2008512428A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2006097458A1 (en) 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
WO2006135479A2 (en) 2005-05-10 2006-12-21 Angiotech International Ag Anti-scarring agents, therapeutic compositions, and use thereof
WO2006138212A1 (en) 2005-06-14 2006-12-28 Gilead Sciences, Inc. SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION
PL1912677T3 (pl) 2005-06-20 2014-03-31 Psma Dev Company L L C Koniugaty przeciwciało PSMA-lek
WO2007054974A2 (en) 2005-09-28 2007-05-18 Arch Pharmalab Limited A green chemistry process for the preparation of pregnadiene esters
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
WO2008015696A2 (en) 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
CA2652945C (en) 2006-05-30 2015-06-02 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
JP2010503722A (ja) 2006-09-19 2010-02-04 シプラ・リミテッド シクレソニドとその結晶変異体の調製方法
WO2008052350A1 (en) 2006-11-03 2008-05-08 Qlt Inc. Photodynamic therapy for the treatment of hidradenitis suppurativa
NO331891B1 (no) 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2173169B1 (en) 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
MX2010005861A (es) 2007-11-30 2010-06-11 Pfizer Ltd Agonistas novedosos de los receptores de glucocorticoides.
CL2008003802A1 (es) 2007-12-21 2010-02-19 Schering Corp Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
JP2011507878A (ja) 2007-12-21 2011-03-10 シェーリング コーポレイション Ｃ２０−ｃ２１置換グルココルチコイド受容体アゴニスト
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
RU2010133722A (ru) 2008-02-27 2012-04-10 Астразенека Аб (Se) 16-альфа, 17-альфа-ацетальглюкокортикостероидные производные и их применение
PT2262823E (pt) 2008-03-13 2013-03-05 Farmabios Spa Processo para a preparação de derivados de pregnano
WO2009152171A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
BRPI0914789A2 (pt) 2008-06-16 2015-10-20 Immunogen Inc efeitos sinérgicos
BRPI0914629A2 (pt) 2008-06-24 2019-09-24 Irm Llc compostos e métodos para a modulação de receptores acoplados à proteína g
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
AU2009322236B2 (en) 2008-12-04 2013-11-07 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR101940059B1 (ko) 2008-12-19 2019-01-18 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5412622B2 (ja) 2009-03-09 2014-02-12 三笠製薬株式会社 ステロイド化合物
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
JP2012528140A (ja) 2009-05-29 2012-11-12 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
CN102665757A (zh) 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
CA2795734A1 (en) 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
ES2685607T3 (es) 2010-06-03 2018-10-10 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
JP2013539353A (ja) 2010-06-24 2013-10-24 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
AU2011305567A1 (en) 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
WO2012089247A1 (en) 2010-12-29 2012-07-05 Nokia Siemens Networks Oy A method and apparatus for transmitting an identity
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
BR112014009810A2 (pt) 2011-10-24 2017-04-25 Abbvie Inc imunoligantes biespecíficos dirigidos contra tnf e il-17
CN104093739A (zh) 2011-10-24 2014-10-08 艾伯维公司 针对tnf的免疫结合剂
US20130115269A1 (en) 2011-11-04 2013-05-09 Henry John Smith Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
CN103421075B (zh) 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US20150158943A1 (en) 2012-06-01 2015-06-11 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
ES2706757T3 (es) 2012-12-21 2019-04-01 Boehringer Ingelheim Vetmedica Gmbh Formulación farmacéutica que comprende ciclesonida
CA2898676A1 (en) 2013-03-15 2014-09-25 Abbvie, Inc. Improved tnf binding proteins
EP3049443A4 (en) 2013-09-27 2017-04-05 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3125943A4 (en) 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
CA2948013A1 (en) 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
EP3193829B1 (en) 2014-09-19 2021-12-08 Oxular Limited Ophthalmic drug compositions
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
JP2016190798A (ja) 2015-03-31 2016-11-10 三笠製薬株式会社 アレルギー性鼻炎治療用局所点鼻薬
EP3307749A4 (en) 2015-06-15 2019-06-19 Hangzhou Dac Biotech Co., Ltd HYDROPHILIC LINKER FOR CONJUGATION
CN107921144B (zh) 2015-06-20 2023-11-28 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
WO2015155753A2 (en) 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Novel linkers and their uses in specific conjugation of drugs to a biological molecule
JP2017066075A (ja) 2015-09-30 2017-04-06 三笠製薬株式会社 リウマチ治療薬
CA3025377A1 (en) 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP6767796B2 (ja) 2016-07-08 2020-10-14 株式会社日立情報通信エンジニアリング 通話管理システム及びその音声認識制御方法
JP7330101B2 (ja) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
PE20201286A1 (es) * 2017-12-01 2020-11-24 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados de este

Also Published As

Publication number Publication date
HUE054428T2 (hu) 2021-09-28
RS61994B1 (sr) 2021-07-30
MX2020005583A (es) 2020-11-25
MA49796A (fr) 2020-06-03
EP3658192B1 (en) 2021-04-28
CL2021001075A1 (es) 2021-10-15
ZA202003325B (en) 2021-07-28
CN111417410A (zh) 2020-07-14
CL2020001452A1 (es) 2020-09-11
US20210015938A1 (en) 2021-01-21
KR20200095477A (ko) 2020-08-10
JP2021501124A (ja) 2021-01-14
IL274651B (en) 2021-04-29
DK3658192T3 (da) 2021-06-21
CR20200239A (es) 2020-09-21
EP3658192A1 (en) 2020-06-03
SG11202004867WA (en) 2020-06-29
CN111417410B (zh) 2023-06-23
JP6813712B2 (ja) 2021-01-13
CY1124230T1 (el) 2022-05-27
CA3082356A1 (en) 2019-06-06
AU2018374634A1 (en) 2020-05-28
DOP2020000116A (es) 2020-08-31
IL274651A (en) 2020-06-30
PT3658192T (pt) 2021-06-25
PE20201286A1 (es) 2020-11-24
LT3658192T (lt) 2021-07-12
TWI803542B (zh) 2023-06-01
EP3884962A1 (en) 2021-09-29
ES2877659T3 (es) 2021-11-17
US10772970B2 (en) 2020-09-15
WO2019106609A1 (en) 2019-06-06
BR112020010694A2 (pt) 2020-11-10
JP2021054845A (ja) 2021-04-08
HRP20210917T1 (hr) 2021-09-03
TW201924723A (zh) 2019-07-01
CO2020006446A2 (es) 2020-06-09
PL3658192T3 (pl) 2021-10-18
RU2020117698A (ru) 2022-01-04
ECSP20029001A (es) 2020-06-30
UY37991A (es) 2019-06-28
UA126595C2 (uk) 2022-11-02
RU2020117698A3 (sl) 2022-01-04
US20190167804A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
ZA201808623B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
ZA202003325B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
IL269065A (en) Paranoid X receptor agonists and uses thereof
IL269068A (en) Paranoid X receptor agonists and uses thereof
HK1257751A1 (zh) 類法尼醇x受體激動劑及其用途
IL276340A (en) PD-1 agonistic antibodies and their uses
IL281475A (en) Paranoid X receptor agonists and uses thereof
IL281471A (en) Farnesoid x receptor agonists and uses thereof
IL281474A (en) Farnesoid x receptor agonists and uses thereof
EP3594221A4 (en) GPR84 RECEPTOR ANTAGONISTS AND USES THEREOF
ZA201906954B (en) Btla agonist antibodies and uses thereof
IL274751A (en) ILDR2 antagonists and combinations thereof
HK1258886A1 (zh) T細胞受體及其用途
EP3445769A4 (en) THYROID HORMONE RECEPTOR AGONIST AND ITS USE
IL266721A (en) Anti-gp73 antibodies and immunoconjugates
EP3384920A4 (en) AGONIST OF THE SPEXIN-BASED GALANIN TYPE-2 RECEPTOR AND USE THEREOF
GB2585607B (en) Chimeric antigen receptor and application thereof
IL269213A (en) Antigen receptors and their uses
GB201700981D0 (en) Composition and device